Anti-Mouse TIM-2 – Purified in vivo PLATINUM™ Functional Grade

Clone RMT2-14 is a monoclonal antibody specific for mouse TIM-2 (T cell immunoglobulin mucin domain-2) and is widely used in in vivo research to study immune regulation, especially regarding Th2 cell responses and autoimmune disease models in mice.

Common in vivo applications of clone RMT2-14 in mice include:

• Functional blockade of TIM-2: RMT2-14 is used to block the interaction between TIM-2 and its ligands in vivo, which can lead to increased T cell proliferation and enhanced Th2 cytokine production.
• Study of autoimmune and inflammatory diseases: In murine models of autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA), administration of RMT2-14 exacerbates disease severity, suggesting that TIM-2 acts as a negative regulator of pathogenic Th2-biased immune responses.
• Assessment of B cell activation: RMT2-14 has been shown to enhance the activation of B cells and increase the production of specific immunoglobulin isotypes (e.g., IgG2b, IgG3) in vivo, which is relevant for studies of antibody-mediated immune mechanisms in disease settings.
• Immunophenotyping and flow cytometry: Although mostly used for functional studies, RMT2-14 can also be used in flow cytometry and immunohistochemistry to identify and characterize TIM-2-expressing cells in tissues.

Key details:

• Mechanistic insight: Blockade of TIM-2 by RMT2-14 disrupts its negative regulatory function, often resulting in heightened immune activation, particularly of Th2 and B cells, which can be experimentally beneficial when studying hyperactive or dysregulated immune responses.
• Disease modeling: RMT2-14 is particularly relevant in studies of allergies, atopic diseases, and models of autoimmune inflammation, where manipulation of TIM-2 signaling alters disease course and immune cell behavior.

In summary, RMT2-14 is primarily used for in vivo blockade of TIM-2 to investigate its role as an immune regulator, particularly in the context of Th2-biased inflammation and autoimmune disease models in mice.

The monoclonal antibody RMT2-14 is widely used as an anti-mouse TIM-2 (T cell immunoglobulin and mucin-domain containing protein 2) antibody in immunology and neuroscience research. In the literature, RMT2-14 is commonly used together with several other antibodies and proteins to investigate immune cell populations, activation, and functional responses.

Commonly co-used antibodies or proteins with RMT2-14 include:

• Other TIM family antibodies:

  • Anti-TIM-1 (RMT1-17)
  • Anti-TIM-3 (RMT3-23)
  • Anti-TIM-4 (RMT4-53)
    These allow simultaneous analysis or differentiation of TIM family protein expression patterns and functions on immune cells.

• Other anti-TIM-2 monoclonals:

  • RMT2-26 is another clone for TIM-2 and may be used in parallel or for comparative epitope mapping studies.

• Anti-CD3 and anti-CD28 antibodies:
  These antibodies are used extensively in T-cell stimulation assays (activation or proliferation of T cells) in cell culture systems to analyze the functional role of TIM-2 signaling in T lymphocytes.

These combinations are particularly useful for:

• Multiparametric flow cytometry to distinguish immune cell subsets and activation profiles.
• Functional assays in which T cells are activated and their response in the presence or absence of TIM-2 engagement is evaluated.

No direct references from your results mention other antibodies consistently paired in published work beyond those above. However, based on established immunological practices, lineage or activation markers (e.g., anti-CD4, anti-CD8, anti-B220, etc.) may also be included in more comprehensive panels involving RMT2-14, depending on the experiment's aim.

Summary Table—Commonly Used Antibodies with RMT2-14

These antibody combinations support detailed characterization of cell surface molecules and cell functions where TIM-2 (and hence RMT2-14) is implicated.

Key findings from scientific literature citing clone RMT2-14 focus on its role as an anti-TIM-2 monoclonal antibody that modulates B cell activity and antibody production in murine models. Specifically, RMT2-14 acts as an agonist for TIM-2 on B cells, enhancing proliferation and immunoglobulin secretion.

• RMT2-14 enhances B cell proliferation: Studies found that the addition of RMT2-14 to cultured mouse splenic B cells significantly increased B cell proliferation compared to control IgG (e.g., 8788 ± 160 vs 9907.5 ± 172.9 cpm, P = 0.003).

• RMT2-14 increases production of specific IgG isotypes: In vitro stimulation of B cells with anti-TIM-2 mAbs like RMT2-14 resulted in heightened secretion of IgG2b and IgG3 isotypes relative to controls, suggesting increased antibody class switching and activation.

• RMT2-14 exacerbates immune-mediated disease: The amplified activation of B cells and increased antibody (Ab) production by RMT2-14 worsened experimental autoimmune conditions such as collagen-induced arthritis (CIA) in mice, likely through its agonistic effects on TIM-2 signaling.

• Mechanistic implications: RMT2-14 does not block but rather promotes the enhancement of B cell activities induced by H-ferritin, indicating its functional role as a TIM-2 agonist rather than an antagonist.

In sum, clone RMT2-14 is predominantly cited for its ability to upregulate B cell activation and antibody secretion via TIM-2 engagement, with implications for autoimmune disease exacerbation in preclinical models. No references were found indicating clinical use or broader therapeutic applications for RMT2-14 outside immunological research.

Dosing regimens for clone RMT2-14 (an anti-mouse TIM-2 antibody) in mouse models are determined by the specific disease context, experimental design, and mouse strain used, but they generally follow established in vivo antibody administration protocols with adjustments as needed for model-specific factors.

Key details:

• The typical dosing regimen for RMT2-14 is designed based on its pharmacokinetics, biological activity, and the intended effect (e.g., blockade vs. depletion) in the specific mouse model.
• Dosing amounts and schedules can vary; however, for most in vivo studies with functional-grade antibodies targeting immune checkpoints in mice, doses often range from 100 μg to 500 μg per mouse per injection, administered intraperitoneally or intravenously.
• The frequency of administration is commonly every 3–4 days, but may be adapted to the specific tumor or immune model and experimental objectives. This aligns with dosing intervals seen for similar antibodies in immuno-oncology studies.
• Tumor models (e.g., syngeneic or xenografts): Dosing is often on the higher end of the range and may be combined with other checkpoint inhibitors or modalities, with adjustments made based on tumor size, growth kinetics, and observed antibody efficacy.
• Specialized models (e.g., autoimmunity or infection): Dose and schedule may be reduced, spaced out, or titrated based on the sensitivity of the model and the desired immunomodulatory effect rather than direct tumor kill.

Sources note that the exact regimen should be empirically tailored as mouse strain, tumor type, immune status, and study goal all influence antibody pharmacodynamics and results. Major reagent suppliers and antibody dosing guides provide standard starting doses but recommend pilot experiments to optimize regimens for new models.

Summary Table: Typical RMT2-14 Dosing in Mouse Models

Model-dependent variation:
Dosing may be increased in models with rapid antibody clearance or highly proliferative tumors, or decreased in sensitive strains or when used in chronic studies. Optimization should consider mouse age, weight, and health as well.

In summary:
The dosing regimen of RMT2-14 in mouse models is generally 100–500 μg per mouse every 3–4 days, with specifics adjusted for the particular disease model and experimental goals, in keeping with standard in vivo antibody protocols.